Trial Profile
A Post-Exposure Prophylaxis Phase III Clinical Trial to Evaluate Protective Efficacy of an Anti-COVID-19 Monoclonal Antibody Treatment Candidate (CT-P59) in Contacts of SARS-CoV-2 Infected Patients
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Regdanvimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
- 16 Jul 2021 Results presented in a Celltrion Media Release.
- 16 Jul 2021 According to a Celltrion media release, data presented at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID).
- 12 Oct 2020 According to a Celltrion media release, the company looks forward to continued data generation as this trial proceeds.